DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

Phase 2

Recruiting

Conditions: Squamous Cell Carcinoma of the Oropharynx
Oropharyngeal Cancer

Interventions: Combination Product: Chemoradiation
Procedure: Surgery
Other: Observation
Radiation: Post-operative radiation

First Posted Date: 2023-06-08

Last Posted Date: 2024-11-05

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 150

Registration Number: NCT05894083

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Cardiac Rehabilitation to Improve Breast Cancer Outcomes

Not Applicable

Terminated

Conditions: Cardiovascular Diseases
Breast Cancer

Interventions: Other: Cardiac Rehab

First Posted Date: 2023-05-22

Last Posted Date: 2025-04-08

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 4

Registration Number: NCT05867667

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

Recruiting

Conditions: Graft Versus Host Disease
Hematopoietic Cell Transplantation
Chronic Lung Disease

First Posted Date: 2023-05-19

Last Posted Date: 2024-10-16

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 375

Registration Number: NCT05866302

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
MD Anderson, Houston, Texas, United States

and more 3 locations

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

Phase 2

Recruiting

Conditions: Secondary Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: FLAG or CLAG Protocol

First Posted Date: 2023-03-23

Last Posted Date: 2024-06-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 20

Registration Number: NCT05780879

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: MUSIC website
Behavioral: web-based tool (MAP- Management of Active surveillance in Prostate Cancer)

First Posted Date: 2023-03-10

Last Posted Date: 2024-06-07

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 40

Registration Number: NCT05764005

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Feasibility and Acceptability of Brief, Telehealth Cognitive Compensatory Training for Pediatric Cancer Patients

Not Applicable

Active, not recruiting

Conditions: Pediatric Cancer

Interventions: Other: Cognitive Compensatory Training

First Posted Date: 2023-01-30

Last Posted Date: 2024-08-20

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 26

Registration Number: NCT05704790

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype

Phase 4

Withdrawn

Conditions: CYP3A4*22

Interventions: Drug: Palbociclib 125Mg Tab
Drug: Ribociclib 200Mg Oral Tablet
Drug: Abemaciclib 150 MG Oral Tablet

First Posted Date: 2023-01-20

Last Posted Date: 2024-02-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT05691400

Metastatic Leiomyosarcoma Biomarker Protocol

Recruiting

Conditions: Leiomyosarcoma

Interventions: Other: Plasma Collection

First Posted Date: 2022-12-16

Last Posted Date: 2024-12-06

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 200

Registration Number: NCT05653388

Locations: 🇺🇸
Dana- Farber, Boston, Massachusetts, United States
🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 6 locations

Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

Not Applicable

Completed

Conditions: Cancer

Interventions: Genetic: DPYD or UGT1A1 variants

First Posted Date: 2022-10-17

Last Posted Date: 2025-05-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 96

Registration Number: NCT05583422

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

CLEAR Care Companion Application

Not Applicable

Completed

Conditions: Bladder Cancer
Radical Cystectomy

Interventions: Behavioral: CLEAR Care Companion (CC) application

First Posted Date: 2022-10-13

Last Posted Date: 2025-01-08

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 28

Registration Number: NCT05578898

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy